We are glad to inform you that we have successfully completed the dossier of Nintedanib 100 and 150mg soft-gel capsules for two different indications; to treat idiopathic pulmonary fibrosis (IPF) and to treat a type of non-small cell lung cancer called ‘adenocarcinoma’.
Intas has developed both Dossiers, with a specific Bioequivalence study for each of the indications.
Please contact us for further information.
